Fresenius SE & Co KGaA/ DE0005785604 /

8/10/2020 10:40:10 AM	Chg. +0.07	Volume	Bid10:40:33 AM	Ask10:40:37 AM	Market Capitalization	Dividend Y.	P/E Ratio
39.12EUR	+0.18%	11,890 Turnover: 465,799.32	39.13Bid Size: 4	39.16Ask Size: 181	22.05 bill.EUR	2.12%	11.70

GlobeNewswire 11/11/2019 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medica...

GlobeNewswire 11/7/2019 eGenesis Announces $100 Million Series B Financing

GlobeNewswire 11/4/2019 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medica...

GlobeNewswire 10/29/2019 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Fresenius Medica...

GlobeNewswire 10/23/2019 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medic...

GlobeNewswire 2/20/2019 Akorn Comments on Fresenius’ Proposed Amended Claims

GlobeNewswire 10/18/2018 Akorn Appeals Fresenius Kabi Ruling

GlobeNewswire 7/16/2018 OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Canada

GlobeNewswire 2/21/2018 Global Kidney Dialysis Equipment and Supplies Markets 2016-2024: Fresenius and Baxter Dominate the M...

TeleTrader 8/7/2017 Fresenius Medical buys NxStage for $2 billion

GlobeNewswire 7/19/2017 Akorn Shareholders Vote to Approve Merger Agreement with Fresenius Kabi

GlobeNewswire 6/9/2017 KISSEI TO MARKET AVACOPAN IN JAPAN FOR VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA

GlobeNewswire 4/7/2017 Akorn Confirms Discussions with Fresenius Kabi

GlobeNewswire 1/27/2011 Swedish Orphan Biovitrum agrees with Fresenius Biotech to distribute Removab®